Dr. Ambreen Roshan reminds patients to stick to the plan their own physician prescribes rather than adjusting tirzepatide themselves.
Recap by typeshit. Post by @caviar_dr_ambreen_roshan on Instagram.
He describes a case where a product sourced from neither Eli Lilly nor a compounding pharmacy was followed by liver failure within six days.
The pharmacists' group says the drug looks promising but urges patients to understand what they risk with unofficial sources, and points to its SafeMedication site.
The pharmacists' group points people to its SafeMedication site for a patient-friendly explainer on retatrutide and why unofficial sources are risky.
He says the woman's retatrutide came from neither Lilly nor a compounding pharmacy, and her liver failed within six days of starting it.
A rundown of two Phase III head-to-head trials comparing Novo's CagriSema with tirzepatide in adults with type 2 diabetes.
The endocrinologist cautions that an interesting effect seen in animals does not mean a compound is suitable for human use.
Loading…